Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 43

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 43
---
 2025, cost of
revenue remained relatively unchanged when compared to the same period in 2024.

Research and Development Expenses

For the three months ended March 31, 2025, research
and development expenses decreased $0.9 million, or 45%, as compared to the same period in 2024. This decrease was primarily attributable
to a decrease in payroll related costs, patent expenses, protypes, and outside consulting costs.

General and Administrative Expenses

For the three months ended March 31, 2025, general
and administrative expenses remained primarily unchanged.

21

Sales and Marketing Expenses

For the three months ended March 31, 2025, sales and
marketing expenses decreased $0.1 million, or 27%, as compared to the same period in 2024. This decrease was primarily attributable to
an overall decrease in payroll related costs.

Grant and Contract Expenses

For the three months ended March 31, 2025, grant and
contract expenses decreased $0.2 million, or 81%, as compared to the same period in 2024. This decrease was primarily attributable to
the decrease in grant and contract revenue described above.

Other Income, Net

For the three months ended March 31, 2025, other income
decreased $2.2 million, or -96%, as compared to the same period in 2024. This decrease was primarily due to a $2.7 million decrease in
the change in value of derivative liabilities offset by $0.5 million in offering costs associated with derivative liabilities in the prior
year.

Liquidity and Capital Resources 

The condensed consolidated financial statements have
been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement
of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability
to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.

For the three months ended March 31, 2025, and 2024,
we incurred net loss of $2.3 million and $0.9 million, respectively, and used cash in operating activities of $1.3 million and
$2.7 million, respectively. We had an accumulated deficit of $284 million and $282 million as of March